Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.
Sanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a new indication that will help it compete with Amgen’s rival from the sa
A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group of new drugs that look set for the European market following backing from regulators.
Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (C
